retatrutide phase 3 triumph 3: Program Results 2026 The data just dropped —

The dynamics of this first wave of offpatent entrants will be shaped not just by the cost of development, but also by regulatory classification, privatemarket affordability, and innovators ability to segment the market with second brands and nextgeneration therapies

The Medicines and Healthcare products Regulatory Agency (MHRA) has warned healthcare professionals to be aware of the potential risk of pulmonary aspiration in patients using glucagon-like peptide-1 (GLP-1) or dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists (GLP-1 RAs), who undergo surgery or procedures with general anaesthesia or deep sedation

Bananas, Strawberries, Power Slim Protein

What concerns me most is the amount of misinformation being spread by individuals who have never prescribed these medications, never followed patients longitudinally, and often rely on fear rather than evidence

Pfizer and Amgen are working on new GLP-1 shots designed to be taken once a month rather than weekly.

The adhesive patches are gentle on the skin, making them suitable for regular use without discomfort